Lakeway, NY — (US MARKET BUZZ) — 12/17/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC), Amgen Inc. (NASDAQ:AMGN), bluebird bio, Inc. (NASDAQ:BLUE).
Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC)’s shares plunged 70.32% to $0.82. The company on Dec. 16 announced enrollment of 486 patients, continuation to final analysis and recommendations of the independent Data and Safety Monitoring Board (DSMB) of the Company’s Phase 3 SEAMLESS study of oral sapacitabine capsules in acute myeloid leukemia (AML). All patients will continue to be followed up until mature data become available for final analysis. The DSMB conducted its planned interim analysis for futility after 247 events and the final safety review of 470 randomized patients. The DSMB found no safety concerns. However, the planned futility boundary has been crossed and the DSMB determined that based on available interim data, it would be unlikely for the study to reach statistically significant improvement in survival.
Amgen Inc. (NASDAQ:AMGN)’s shares gained 0.31% to $160.10. Amgen and AstraZeneca (AZN) on Dec. 11 announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in patients with moderate-to-severe plaque psoriasis will be presented at the Psoriasis: From Gene to Clinic International Congress in London on Saturday, Dec. 13, 2014, at 11:20 a.m. GMT (Abstract FC30). Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 cytokines (A, F and A/F) to the receptor. The IL-17 receptor and cytokine family play a central role in the development and clinical manifestations of plaque psoriasis.
bluebird bio, Inc. (NASDAQ:BLUE)’s stock declined 1.29% to $85.11. The company on Dec. 15 announced the pricing of an underwritten public offering of 2,650,000 shares of its common stock at a public offering price of $85.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 397,500 shares of common stock. BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers of the proposed offering. SunTrust Robinson Humphrey, Wedbush PacGrow Life Sciences and Roth Capital Partners are acting as co-managers. The offering is expected to close on or about December 19, 2014, subject to customary closing conditions.
thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.